| Literature DB >> 35661984 |
Jaeseo Lee1, Seon Ju Mun1,2, Yongbo Shin1,2, Seonbhin Lee1,2, Myung Jin Son3,4.
Abstract
Reliable in vitro models with human-derived cells that recapitulate in vivo-like physiologies are required for drug discovery and development to reduce the gap between the results of cell-based drug testing, animal testing, and human clinical trials. Liver organoid models have emerged as novel tools for hepatotoxicity evaluation, liver disease modeling, and drug screening. Liver organoids can be generated from biopsies of liver tissues or pluripotent stem cells and can be applied to various liver diseases, including metabolic associated fatty liver disease, infectious liver disease, genetic liver disease, and liver cancer. This review focuses on recent studies on organoids to model human liver diseases and discusses the advantages and limitations of current liver organoids for translational applications.Entities:
Keywords: Disease model; Drug screening; Liver; Organoids
Mesh:
Year: 2022 PMID: 35661984 DOI: 10.1007/s12272-022-01390-6
Source DB: PubMed Journal: Arch Pharm Res ISSN: 0253-6269 Impact factor: 4.946